Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
This prospective observational study aimed to evaluate the clinical utility of first trimester screening markers, including serum Beta human chorionic gonadotropin (ß‐hCG), Pregnancy‐associated plasma protein‐A (PAPP‐A) and Nuchal translucency (NT) measurements, in detecting fetal aneuploidies and assessing fetal outcomes. Primigravidae with singleton pregnancies underwent first‐trimester screening between 11+0‐13+6 weeks of gestation, comprising serum ß‐hCG and PAPP‐A measurements, along with NT ultrasonography. Pregnancy outcomes were monitored, including medical termination, miscarriages, stillbirths, low birth weight, intrauterine growth retardation, preterm birth and intrauterine death. Patients with positive screening results underwent confirmatory testing via amniocentesis. Among 115 patients, four screened positive, of whom three were diagnosed with Down syndrome and one tested negative for aneuploidy. Statistical analysis revealed a sensitivity and specificity of 75% and 63%, respectively, for the combined markers and NT in detecting chromosomal abnormalities. Maternal serum ß‐hCG, PAPP‐A and NT measurements in the first trimester serve as valuable screening tools for assessing the risk of fetal trisomies. Early identification enables informed decision‐making regarding diagnostic testing and potential options for safe termination, thereby enhancing prenatal care and management strategies.
How to cite this article:
Shaikh Reshma, Anoop Kanthi, Seema Chigateri and Vivek Hoskeri. First Trimester Screening for Fetal Aneuploidy and its Outcome.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.11.14.18
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.11.14.18